Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Pediatric Rheumatology Year in Review, 2021: Basic Science

Elizabeth Sloan, MD  |  December 9, 2021

ACR Convergence 2021—The field of pediatric rheumatology has benefited from significant developments in the basic and translational sciences over the past year, and it can be challenging to keep up with the latest discoveries. In the Basic Science section of the Pediatric Rheumatology Year in Review at ACR Convergence, Tiphanie Vogel, MD, PhD, assistant professor of pediatric and adult rheumatology, Texas Children’s Hospital and Baylor College of Medicine, Houston, highlighted several key studies that have significant implications for advancing our knowledge of pediatric rheumatic diseases.

Dr. Vogel

Molecular Patterns

Dr. Vogel began by presenting her personal favorite publication of the year, which was a collaborative effort between industry and several academic centers in Europe. Barturen et al. introduced their study by acknowledging that systemic autoimmune diseases are clinically heterogeneous.1 Further, even if patients appear similar to one another clinically, they often respond differently to treatment.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Using high dimensional analysis of genome, transcriptome and methylome data, the investigators discovered that subjects clustered into four distinct molecular patterns: inflammatory, lymphoid, interferon and undefined. The undefined, or non-pathologic, cluster included healthy controls and those with low disease activity. Each cluster included all diagnoses, although certain clusters were enriched by specific diseases.

With longitudinal data, researchers were able to demonstrate that when some subjects went into remission, they were able to move from their pathologic cluster into the undefined cluster. During a disease flare, the same subjects would return to their initial pathologic cluster, suggesting these molecular patterns are inherent to the patient, regardless of their autoimmune disease diagnosis. “If you’re like me and you’re really interested in the idea of targeted therapy based on molecular patterns, then this is a really powerful paper,” Dr. Vogel said.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

SLE Studies

Next, she drew attention to several studies in patients with systemic lupus erythematosus (SLE), including several neutrophil-related papers, but she chose to highlight a study on the role of erythroid lineage cells in lupus. Caielli et al. described how a subset of patients with active SLE inappropriately retain mitochondria in their red blood cells due to a missing metabolic signal.2 Opsonization of mitochondria-positive red blood cells is highly inflammatory and correlates with enhanced interferon signatures and increased disease activity.

The investigators also found mitochondrial retention did not occur in healthy controls or in patients with juvenile dermatomyositis, but it did occur in patients with chronic atypical neutrophilic dermatosis with lipodystrophy, an autoinflammatory disease characterized by high interferon signatures. Dr. Vogel explained that this provides evidence for potential subgrouping of SLE patients and may allow for new therapeutic targets in the future.

Page: 1 2 3 4 | Single Page
Share: 

Filed under:ACR ConvergenceConditionsMeeting ReportsPediatric ConditionsSystemic Lupus Erythematosus Tagged with:ACR Convergence 2021ACR Convergence 2021 – SLECOVID-19DADA2Pediatric

Related Articles

    ADA2 Mutation Connects Vascular Pathology to Immunodeficiency

    June 13, 2014

    Two new studies that examine the effects of a genetic defect in adenosine deaminase 2 may advance a gene-based definition of vasculopathy

    DADA2 Research Reveals Mechanisms & Possible Gene Therapy

    February 18, 2018

    SAN DIEGO—An increasing number of patients is being identified with deficiency of adenosine deaminase type 2 (DADA2); fortunately, researchers and clinicians continue to better understand the genetic disease as well, experts said in a session at the 2017 ACR/ARHP Annual Meeting Nov. 3–8. The childhood-onset disease involves loss-of-function mutations to the CECR1 gene (i.e., cat…

    COPA Syndrome: What Do We Know About This Rare Disease?

    April 17, 2021

    ACR CONVERGENCE 2020—Tiphanie Phillips Vogel, MD, PhD, assistant professor of pediatrics and internal medicine at Baylor College of Medicine, Houston, moderated the session on COPA syndrome, which drew 324 attendees on a Sunday morning. This rare genetic cause of immune dysregulation can present like anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis, lupus, lupus nephritis or rheumatoid…

    Updates in Pediatric Lupus: Experts Discuss Advances in Lupus Nephritis Treatments, Monogenic Lupus & More

    August 31, 2021

    PRSYM—At the 2021 Pediatric Rheumatology Symposium (PRSYM), a session on lupus provided a robust discussion of recent advances in lupus treatments and genetic discoveries in pediatric rheumatology. Lupus Nephritis The first speaker was Shaun Jackson, MD, PhD, a pediatric nephrologist and rheumatologist and associate professor at Seattle Children’s. His presentation focused on state-of-the-art treatments in…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences